Related Experiment Video
Updated: Jan 22, 2026

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization
Published on: June 7, 2016
Survival analysis of breast cancer patients with different treatments: a multicentric clinicopathological study
Saima Shakil Malik1, Mehreen Baig2, Muhammad Bilal Khan3
1Fatima Jinnah Women University, Rawalpindi.
Objective:
To explore and better understand clinic pathological details of breast cancer patients and analyse their survival rate among different treatment groups.
Methods:
The prospective cohort, multi-centric study was conducted from September, 2014, to February, 2018, at five hospitals in Rawalpindi and Islamabad, Pakistan, and comprised histo-pathologically confirmed breast cancer cases. Patient characteristics and medical history were collected using a detailed questionnaire. All the subjects were followed up, and information regarding their current health and treatment status was collected. Data was analysed using SPSS 24.
Results:
There were 347 subjects with a mean age of 44.3±12.2 years and body mass index of 27.9±4.0 kg/m2. Younger age, increased body mass index, consanguinity and family history were major contributing factors in breast cancer development (p<0.05). Overall, 267(77%) had invasive ductal carcinoma and Grade II tumour 234(67%) was more frequent. A total of 221(64%) cases had positive lymph nodes and 97(28%) had metastasis to different body organs. Overall survival analysis showed statistically significant role (p<0.0001) of all treatment options.
Conclusions:
Combination of different treatments can provide more promising health outcomes in breast cancer cases.
Related Concept Videos
Cancer Survival Analysis
Introduction To Survival Analysis
The primary goal of survival analysis is to estimate survival time—the time...
Comparing the Survival Analysis of Two or More Groups
Truncation in Survival Analysis
Left truncation occurs when individuals who experienced the event of interest before a certain time are not included in the study. This is often due to a "delayed entry" into the study where only those who survive until a certain entry point are...
Assumptions of Survival Analysis
Treatment Resistant Cancers

